STOCK TITAN
  1. Home
  2. Sec-filings
  3. ZNTL
  4. [Form 4] Zentalis Pharmaceuticals, Inc. Insider Trading Activity

RSU grant boosts Zentalis (ZNTL) director Jan Skvarka's holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Skvarka Jan reported acquisition or exercise transactions in this Form 4 filing.

Zentalis Pharmaceuticals director Jan Skvarka received 57,100 restricted stock units as equity compensation. The grant was made at no cash cost and will vest on the earlier of June 16, 2027 or the next annual stockholder meeting, subject to continued board service. Following this award, Skvarka holds 264,254 shares/units of common stock.

Positive

  • None.

Negative

  • None.
Insider Skvarka Jan
Role null
Type Security Shares Price Value
Grant/Award Common Stock 57,100 $0.00 --
Holdings After Transaction: Common Stock — 264,254 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSUs granted 57,100 units Restricted stock units granted to director Jan Skvarka
Grant price $0.0000 per unit Equity award granted at no cash cost
Holdings after grant 264,254 shares/units Total common stock position following the transaction
Vesting date June 16, 2027 Or earlier at the next annual stockholder meeting
restricted stock units financial
"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Non-Employee Director Compensation Program financial
"granted pursuant to the Issuer's Non-Employee Director Compensation Program"
contingent right to receive one share of common stock financial
"each of which represents a contingent right to receive one share of common stock"
vesting date financial
"subject to the Reporting Person's continued service ... through such vesting date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Skvarka Jan
(Last)(First)(Middle)
C/O ZENTALIS PHARMACEUTICALS, INC.
10275 SCIENCE CENTER DRIVE, SUITE 200
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Zentalis Pharmaceuticals, Inc. [ ZNTL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/16/2026A57,100(1)A$0264,254D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ James B. Bucher, attorney-in-fact for Jan Skvarka06/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Zentalis (ZNTL) director Jan Skvarka report in this Form 4?

Jan Skvarka reported receiving 57,100 restricted stock units of Zentalis common stock as an equity award. The units were granted at no cash cost and reflect compensation under the company’s Non-Employee Director Compensation Program.

How many Zentalis (ZNTL) shares does Jan Skvarka hold after this grant?

After the reported grant, Jan Skvarka holds 264,254 shares or units of Zentalis common stock. This figure includes the newly awarded 57,100 restricted stock units reported in the Form 4 insider filing.

What are the vesting terms of Jan Skvarka’s 57,100 RSUs at Zentalis (ZNTL)?

The 57,100 restricted stock units will vest on the first to occur of June 16, 2027 or the next annual meeting of Zentalis stockholders, provided Skvarka continues serving on the board through the applicable vesting date.

Does Jan Skvarka pay cash for the 57,100 Zentalis (ZNTL) RSUs?

No cash payment is required for this award. The Form 4 shows a price per share of $0.0000, indicating the 57,100 restricted stock units were granted as non-cash equity compensation under the director compensation program.

What does each restricted stock unit represent for Zentalis (ZNTL) director Jan Skvarka?

Each restricted stock unit represents a contingent right to receive one share of Zentalis common stock. Actual shares will be delivered when the units vest, assuming Skvarka satisfies the continued board service requirement through the vesting date.